Clinical Trials for Hormone Receptor Positive HER-2 Negative Breast Cancer

Find clinical trials for hormone receptor positive her-2 negative breast cancer. Discover research opportunities and treatment options in your area.

9 Active Trials Found

Showing 9 trials on this page

Page 1 of 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT ID: NCT06257264

This clinical trial is studying a new treatment called BG-68501 for patients with advanced-stage tumors, including certain types of breast cancer, lung cancer, ovarian cancer, and others. The main ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Saint Louis, Missouri, United States, Brisbane, Queensland, Australia +44 more

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT ID: NCT06369285

This clinical trial, called PUMA-ALI-1201, is studying a medication called alisertib when used together with hormone therapy for patients who have a specific type of breast cancer known as hormone ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Rochester, Minnesota, United States, Boston, Massachusetts, United States +46 more

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT ID: NCT06120283

This clinical trial is studying a new medication called BGB-43395, which targets a specific protein involved in cell growth, to see how well it works on its own or in combination with other treatme...

Recruiting

Phase: PHASE1 Type: interventional Locations: Saint Louis, Missouri, United States, Bangkok, , Thailand +84 more

VS-6766+Abema+Fulv in Met HR+/HER- BC

NCT ID: NCT05608252

This clinical trial is investigating the safety and effectiveness of a new combination treatment for patients with hormone receptor-positive, HER2-negative breast cancer that has either spread or c...

Recruiting

Phase: PHASE1 Type: interventional Locations: Boston, Massachusetts, United States, Boston, Massachusetts, United States +1 more

Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT ID: NCT05573126

This clinical trial is investigating a new treatment called EP0062 for women with a specific type of breast cancer known as hormone receptor-positive, HER2-negative, and AR+ (androgen receptor-posi...

Recruiting

Phase: PHASE1 Type: interventional Locations: Boston, Massachusetts, United States, Detroit, Michigan, United States +13 more

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

NCT ID: NCT06805812

The PALMARES-2 study is looking at how well certain treatments work for patients with advanced hormone receptor-positive, HER2-negative breast cancer. Specifically, it focuses on patients who are r...

Recruiting

Type: observational Locations: Rozzano, , Italy, Genova, , Italy +22 more

Evaluating the Addition of Elacestrant (oral SERD) to Olaparib (PARP-inhibitor) in Patients with Advanced/metastatic HR+/HER2- Breast Cancer

NCT ID: NCT06201234

This clinical trial is looking at whether adding a new oral medication called elacestrant to the standard treatment of olaparib can help patients with advanced hormone receptor-positive, HER2-negat...

Recruiting

Phase: PHASE2 Type: interventional Locations: Hannover, , Germany, Frankfurt Am Main, Hessen, Germany +1 more

Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer

NCT ID: NCT05878314

The PEAK trial is studying how the menstrual cycle may affect the levels of a marker called Ki67 in women with hormone receptor-positive, HER2-negative breast cancer. This trial is looking for wome...

Recruiting

Type: observational Locations: Tuebingen, , Germany

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

NCT ID: NCT05901428

This clinical trial is looking at two different chemotherapy treatments for women with early-stage, high-risk breast cancer that is hormone receptor-positive and HER2-negative (meaning it does not ...

Recruiting

Phase: PHASE3 Type: interventional Locations: Shanghai, Shanghai, China

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions